Therapeutics

Clinical Research Associates, L.L.C. (CRA) is an affiliate of the Simons Foundation. Its goals include supporting research that will lead to better ways to prevent and treat autism spectrum disorder (ASD) and improve the lives of individuals with autism.

The primary activity of CRA is to enable development of new treatments and supports for individuals and families with autism.

CRA is evaluating new potential therapies for ASD, including R-baclofen (also known as arbaclofen or STX209) and other drugs.

CRA has purchased sufficient quantities of R-baclofen (both drug product and active pharmaceutical ingredient) to conduct future trials to explore its potential efficacy in treating ASD-affected individuals.

CRA is currently considering applications to obtain R-baclofen for investigator-initiated studies in humans and animals. If you are interested in applying, please send an e-mail to applications@clinicalresearchassociates.net.

Additional Links
Subscribe to our newsletter and receive SFARI funding announcements and news